<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00742872</url>
  </required_header>
  <id_info>
    <org_study_id>AUB-IM.AS1.21</org_study_id>
    <nct_id>NCT00742872</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Mosapride Versus Placebo in the Treatment of Constipation-Predominant Irritable Bowel Syndrome</brief_title>
  <official_title>A Prospective Double-Blind Placebo-Controlled Trial of Mosapride in Patients With Constipation-Predominant Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American University of Beirut Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American University of Beirut Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Mosapride, an agent which acts on serotonin
      receptors in the gastrointestinal tract, is effective in the treatment of
      constipation-predominant irritable bowel syndrome (C-IBS).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor recruitment, high drop out rate
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adequate Relief of Symptoms Associated With Constipation-predominant Irritable Bowel Syndrome.</measure>
    <time_frame>Within the first 8 weeks of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Constipation-Predominant Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mosapride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mosapride Citrate</intervention_name>
    <description>One 5 mg tablet taken orally three times per day (15 min before meals) for 8 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Mosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One tablet (identical in shape and form to the actual drug) taken orally three times per day (15 min before meals) for 8 weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rome III Criteria for IBS:

        Patients must have recurrent abdominal pain or discomfort at least 3 days per month during
        the previous 3 months that is associated with 2 or more of the following:

          -  Relieved by defecation

          -  Onset associated with a change in stool frequency

          -  Onset associated with a change in stool form or appearance

        In addition, patients have to experience at least two of the following symptoms for at
        least 25% of the time [11]:

          -  Altered stool frequency (&lt; 3 bowel movements per week)

          -  Altered stool form (lumpy/hard i.e. Bristol type I-III [see appendix 1])

          -  Altered stool passage (straining, urgency, or a feeling of incomplete evacuation)

          -  Passage of mucus, bloating, or a feeling of abdominal distension

        Exclusion Criteria:

          -  Previous allergy to mosapride

          -  Nocturnal Symptoms (pain in the middle of the night, or other nocturnal symptoms which
             suggest an organic disease)

          -  Age &lt; 18 years

          -  History of bloody stools or melena

          -  Diarrhea (&gt;3 bowel movements per day)

          -  Constitutional symptoms (fever, weight loss)

          -  Severe constipation (&lt; 1 bm/week)

          -  Pregnancy or lactation

          -  Patients with history of cardiac arrhythmias

          -  QT prolongation on baseline ECG

          -  Chronic laxative use and dependence

          -  Patients with previous history of congenital heart disease

          -  Patients with previous history of hypokalemia or hyperkalemia

          -  Patients taking the following classes of drugs: HIV antivirals, macrolides,
             anti-arrhythmics, and azole drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ala' I. Sharara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>American University of Beirut Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nabil M. Mansour, MD</last_name>
    <role>Study Director</role>
    <affiliation>American University of Beirut Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>American University of Beirut Medical Center</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2008</study_first_submitted>
  <study_first_submitted_qc>August 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2008</study_first_posted>
  <results_first_submitted>February 27, 2013</results_first_submitted>
  <results_first_submitted_qc>February 27, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 9, 2013</results_first_posted>
  <last_update_submitted>February 27, 2013</last_update_submitted>
  <last_update_submitted_qc>February 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>American University of Beirut Medical Center</investigator_affiliation>
    <investigator_full_name>Nabil Mansour</investigator_full_name>
    <investigator_title>assistant professor</investigator_title>
  </responsible_party>
  <keyword>Mosapride</keyword>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>Constipation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mosapride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study</title>
          <description>Mosapride
Mosapride Citrate : One 5 mg tablet taken orally three times per day (15 min before meals) for 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo
Placebo : One tablet (identical in shape and form to the actual drug) taken orally three times per day (15 min before meals) for 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study</title>
          <description>Mosapride
Mosapride Citrate : One 5 mg tablet taken orally three times per day (15 min before meals) for 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo
Placebo : One tablet (identical in shape and form to the actual drug) taken orally three times per day (15 min before meals) for 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="17"/>
                    <measurement group_id="B2" value="41" spread="16"/>
                    <measurement group_id="B3" value="43" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Lebanon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adequate Relief of Symptoms Associated With Constipation-predominant Irritable Bowel Syndrome.</title>
        <time_frame>Within the first 8 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study</title>
            <description>Mosapride
Mosapride Citrate : One 5 mg tablet taken orally three times per day (15 min before meals) for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo : One tablet (identical in shape and form to the actual drug) taken orally three times per day (15 min before meals) for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Adequate Relief of Symptoms Associated With Constipation-predominant Irritable Bowel Syndrome.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Study</title>
          <description>Mosapride
Mosapride Citrate : One 5 mg tablet taken orally three times per day (15 min before meals) for 8 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo
Placebo : One tablet (identical in shape and form to the actual drug) taken orally three times per day (15 min before meals) for 8 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>High placebo response rate, high dropout rate.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Ala Sharara</name_or_title>
      <organization>American University of Beirut Medical Center</organization>
      <phone>+961-3-350000</phone>
      <email>as08@aub.edu.lb</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

